180 related articles for article (PubMed ID: 23562498)
1. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.
Diaz-Padilla I; Romero N; Amir E; Matias-Guiu X; Vilar E; Muggia F; Garcia-Donas J
Crit Rev Oncol Hematol; 2013 Oct; 88(1):154-67. PubMed ID: 23562498
[TBL] [Abstract][Full Text] [Related]
2. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
4. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
5. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
8. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer risk and survival by tumor MMR status.
Nagle CM; O'Mara TA; Tan Y; Buchanan DD; Obermair A; Blomfield P; Quinn MA; Webb PM; Spurdle AB;
J Gynecol Oncol; 2018 May; 29(3):e39. PubMed ID: 29533022
[TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological features associated with mismatch repair deficiency in endometrial undifferentiated/dedifferentiated carcinoma: A systematic review and meta-analysis.
Travaglino A; Raffone A; Gencarelli A; Saracinelli S; Riccardi C; Mollo A; Zullo F; Insabato L
Gynecol Oncol; 2021 Feb; 160(2):579-585. PubMed ID: 33276986
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
16. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
17. Correlation between patient weight and defects in DNA mismatch repair: is this the link between an increased risk of previous cancer in thinner women with endometrial cancer?
Cohn DE; Pavelka JC; Frankel WL; Morrison CD; Hampel H; Copeland LJ; Fowler JM
Int J Gynecol Cancer; 2008; 18(1):136-40. PubMed ID: 17466051
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
20. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
